title: Effect of timolol on refractive outcomes in eyes with myopic regression after laser in situ keratomileusis: a prospective randomized clinical trial.
abstract: OBJECTIVE
  To compare the effects of timolol on refractive outcomes in eyes with myopic regression after laser in situ keratomileusis (LASIK) with a control-matched group.
  
  
  METHODS
  Prospective, randomized, parallel-controlled, double-masked clinical trial. A computer-generated randomization list based on random block permutation (length 4 to 8) was used for treatment allocation.
  
  
  METHODS
  setting: Basir Eye Center, Tehran, Iran.
  
  
  METHODS
  Of 124 eyes with myopic regression after LASIK using Technolas 217-Z, 45 eyes in each group were analyzed.
  
  
  METHODS
  Patients were randomly assigned into either Group 1, who received timolol 0.5% eye drops, or Group 2, who received artificial tears for 6 months.
  
  
  METHODS
  Spherical equivalent (SE) at 6 months posttreatment.
  
  
  RESULTS
  In Group 1, SE improved from -1.48 ± 0.99 diopter (D) before treatment to -0.88 ± 0.91 D and -0.86 ± 0.93 D 6 months after treatment and 6 months after timolol discontinuation, respectively (P < .001). In Group 2, it was -1.57 ± 0.67 D, -1.83 ± 0.76 D, and -1.91 ± 0.70 D, respectively (P < .001). SE was significantly better in Group 1 6 months after treatment and 6 months after discontinuation of treatment (P < .001 for both comparisons). There was a 0.26 D decrease in SE improvement every 4 months after the surgery in the Group 1 (P < .001).
  
  
  CONCLUSIONS
  Timolol application is effective for the treatment of myopic regression after LASIK compared with control group. Its effects last for at least 6 months after its discontinuation.
authors.affiliation: Research Department, Basir Eye Center, Tehran, Iran.
authors.forename: Ahmad
authors.initials: A
authors.lastname: Shojaei
authors.forename: Medi
authors.initials: M
authors.lastname: Eslani
authors.forename: Yasaman
authors.initials: Y
authors.lastname: Vali
authors.forename: Mohammad
authors.initials: M
authors.lastname: Mansouri
authors.forename: Nima
authors.initials: N
authors.lastname: Dadman
authors.forename: Mehdi
authors.initials: M
authors.lastname: Yaseri
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects / Q000502:physiology; D020731:Keratomileusis, Laser In Situ; D054018:Lasers, Excimer / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000503:physiopathology / Q000517:prevention & control* / Q000601:surgery*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D011446:Prospective Studies; D012029:Refraction, Ocular / Q000187:drug effects* / Q000502:physiology; D013999:Timolol / Q000008:administration & dosage*; D014792:Visual Acuity / Q000187:drug effects* / Q000502:physiology; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D013999:Timolol